Source comparison
Receptor Mechanism: GHRH Analog vs Ghrelin Mimetic
CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary, mimicking endogenous GHRH but resisting dipeptidyl peptidase-IV (DPP-IV) degradation through a modified amino acid sequence at positions 2, 8, 15, and 27. The DAC modification. A
This comparison does not assign a generated winner or score.
- CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary, mimicking endogenous GHRH but resisting dipeptidyl peptidase-IV (DPP-IV) degradation through a modified amino acid sequence at positions 2, 8, 15, and 27. The DAC modification. A maleimido-propionic acid linker conjugated to lysine. Allows non-covalent binding to serum albumin, which shields the peptide from renal clearance and proteolytic cleavage. This mechanism produces GH elevations that mirror natural pulsatile secretion patterns but with 2–3× amplitude and 6–8× duration compared to unmodified GHRH. Research from Massachusetts General Hospital demonstrated that CJC-1295 DAC administration resulted in mean IGF-1 increases of 1.5–3× baseline sustained across 168 hours post-injection.
- GHRP-6 operates through an entirely different pathway: ghrelin receptor (GHS-R1a) agonism. Ghrelin receptors exist not only in the pituitary but also in the hypothalamus (arcuate nucleus), where they inhibit somatostatin secretion. The hormone that normally suppresses GH release between physiological pulses. By simultaneously stimulating pituitary GH secretion and blocking hypothalamic somatostatin output, GHRP-6 produces GH spikes 5–15× baseline within 20–30 minutes of administration. The trade-off: plasma GH returns to baseline within 2–4 hours as the peptide is rapidly cleared via renal filtration and enzymatic degradation. A 2019 study published in Endocrine found peak GH concentrations of 18–42 ng/mL at 30 minutes post-GHRP-6 injection, compared to 3–8 ng/mL sustained levels with CJC-1295 DAC.
- The CJC-1295 vs GHRP-6 acetate which better comparison at the receptor level: CJC-1295 enhances what the body already does; GHRP-6 forces what the body is actively trying to prevent.